Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- GNFT.PA
- Price
- 3.13
- Stock movement down
- -0.14 (-4.28%)
- Company name
- Genfit
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 156.21M
- Ent value
- 191.98M
- Price/Sales
- 1.69
- Price/Book
- 1.60
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 110.24
- Forward P/E
- 104.33
- PEG
- -
- EPS growth
- -25.61%
- 1 year return
- -6.57%
- 3 year return
- -3.45%
- 5 year return
- -31.20%
- 10 year return
- -21.63%
Last updated: 2025-04-05
DIVIDENDS
GNFT.PA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 110.24 |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.69 |
| Price to Book | 1.60 |
| EV to Sales | 2.08 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 49.91M |
| EPS (TTM) | 0.02 |
| FCF per share (TTM) | -1.16 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 92.48M |
| Gross profit (TTM) | 95.25M |
| Operating income (TTM) | -6.03M |
| Net income (TTM) | 1.42M |
| EPS (TTM) | 0.02 |
| EPS (1y forward) | 0.03 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 102.99% |
| Operating margin (TTM) | -6.52% |
| Profit margin (TTM) | 1.53% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 61.65M |
| Net receivables | 71.04M |
| Total current assets | 136.38M |
| Goodwill | 0.00 |
| Intangible assets | 46.95M |
| Property, plant and equipment | 0.00 |
| Total assets | 194.78M |
| Accounts payable | 8.04M |
| Short/Current long term debt | 67.80M |
| Total current liabilities | 36.43M |
| Total liabilities | 97.41M |
| Shareholder's equity | 97.36M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -67.39M |
| Capital expenditures (TTM) | 3.15M |
| Free cash flow (TTM) | -69.92M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 1.46% |
| Return on Assets | 0.73% |
| Return on Invested Capital | 1.34% |
| Cash Return on Invested Capital | -66.35% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.26 |
| Daily high | 3.28 |
| Daily low | 3.04 |
| Daily Volume | 349K |
| All-time high | 67.02 |
| 1y analyst estimate | 9.45 |
| Beta | 1.12 |
| EPS (TTM) | 0.02 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| GNFT.PA | S&P500 | |
| Current price drop from All-time high | -95.33% | -17.56% |
| Highest price drop | -95.89% | -56.47% |
| Date of highest drop | 10 Dec 2021 | 9 Mar 2009 |
| Avg drop from high | -68.08% | -11.07% |
| Avg time to new high | 130 days | 12 days |
| Max time to new high | 2593 days | 1805 days |
COMPANY DETAILS
Marketcap
156.21M
Marketcap category
Small-cap
Description
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
Employees
169
Website
Investor relations
-
SEC filings
CEO
Country
France
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
GENFIT completes a royalty financing of up to €185 million with HCRx after unanimous OCEANE bondholder approval, triggering a €130 million upfront payment with potential for an additional €55 million ...
March 20, 2025
All resolutions approved by bondholders Closing of Royalty Financing and receipt of first €130 million instalment expected shortlyUpon closing of the Royalty Financing, GENFIT will implement the Repur...
March 10, 2025
Cash and cash equivalents totaled €81.8 million as of December 31, 2024Revenues amounted to €67.0 million as of December 31, 2024 including the €48.7 million milestone upon first sale of Ipsen’s Iqirv...
February 27, 2025
Put Option Agreements signed to date with 2025 OCEANEs holders representing 95.3% of the outstanding 2025 OCEANEs2025 OCEANEs holders' general meeting convened for March 10, 2025 Lille (France), Cambr...
February 21, 2025
In conjunction with the royalty financing deal with HealthCare Royalty (HCRx) announced on January 30, 2025, GENFIT will request the consent of the holders of 2025 OCEANEs and proposes: to repurchase ...
February 10, 2025
2 new ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on-going UNVEIL-IT® Phase 2 trialData of on-going Phase 1b...
February 6, 2025
GENFIT signs royalty financing deal with HealthCare Royalty (HCRx) providing up to €185 million non-dilutive capital: €130 million upfront, with eligibility to receive up to €55 million in two additio...
January 30, 2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the...
January 29, 2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 13, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the ...
January 13, 2025
PBC program (licensed to Ipsen): Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch of Iqirvo® (elafibranor)1 on track with expectations; encouraging feedback from healthcare pr...
November 13, 2024
Next page